Recent Articles
Posted By: Michael C. Soulen, MD
Sun Jan 13th, 2013
One of the exciting developments in IO research has been the investment by industry in prospective clinical trials to help define best practice in the care of our patients. Nordion, Merit/Biosphere, Sirtex, BTG/Biocompatibles, Siemens, and Delcath all sponsor multicenter Phase 2 and 3 trials...
Posted By: Michael C. Soulen, MD
Mon Jan 7th, 2013
A few months ago, my hospital expanded its patient web access so that patients can read their diagnostic radiology reports a week after the report has been finalized. While in principle I think this is a good thing, the results for cancer patients were predictable.
Posted By: Michael C. Soulen, MD
Mon Nov 12th, 2012
If there were level one evidence to support a particular practice, there wouldn’t be much of a debate! The popularity of this theme is a sign of the lack of clear cut best practice in what is a large and developing part of many interventional radiology practices.
Posted By: Michael C. Soulen, MD
Mon Oct 29th, 2012
I met a new patient in clinic this week who has a solitary pulmonary nodule that has been followed with serial CT scans for a year, contains calcification, is FDG-PET-negative, and was biopsied with no evidence of malignant cells. It grew from 14mm to 17mm on the latest CT, and he came self-referred
Posted By: Michael C. Soulen, MD
Mon Sep 24th, 2012
What is an Interventional Oncology practice? In my highly specialized university center, it’s embolizations and ablations (about 500 a year), palliative procedures for luminal access (GI, GU, biliary - over 400), fluid drainage (over 1000), and venous access (over 2000) -- but very few percutaneous
